MAX - SHOCK Clinical Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
About this trial
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued.
Hypothesis:
ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)
Eligibility criteria
Qualifiers
Patients age > 18 years.
Persistent atrial fibrillation.
Scheduled for elective cardioversion at UOHI
Patient is within the circle of care of UOHI Electrophysiology staff
Disqualifiers
Known left-atrial appendage thrombus.
Contraindication to appropriate anticoagulation.
Patient is included in another randomized clinical trial.
Patient does not meet all of the above listed inclusion criteria.
Trial design
Treatments tested in this trial
- biphasic defibrillator with maximum energy of 200J (® Zoll)
- biphasic defibrillator with maximum energy of 360J (® Physio-Control)
Treatment groups
376 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov